stub Australia Pioneers World's First CBD Pill for Chronic Pain Relief in Groundbreaking Trial -
Connect with us

Industry News

Australia Pioneers World’s First CBD Pill for Chronic Pain Relief in Groundbreaking Trial



In a groundbreaking initiative, Australia is set to lead the world in the development of a revolutionary cannabis pill designed to bring relief to chronic pain. This world-first CBD tablet, currently undergoing a phase 3 clinical trial led by Promethean BioPharma, aims to provide a faster onset of action lasting up to six hours.

Australia's progressive move towards developing the first CBD tablet for pain positions the country at the forefront of global innovation in medicinal cannabis. The clinical trial, a significant step toward gaining approval for CBD as an over-the-counter pain medication, is anticipated to pave the way for its release to consumers at the beginning of 2025.

The trial, reported by 7News Australia, seeks to reaffirm the widely acknowledged potential of CBD in alleviating mild to moderate pain. Importantly, this innovative pill is THC-free, ensuring consumers can experience the therapeutic benefits of CBD without the psychoactive effects associated with THC.

The phase 3 clinical trial, conducted by Promethean BioPharma, is not only a testament to Australia's commitment to advancing medical cannabis research but also a crucial step in establishing CBD as a mainstream pain relief option. The pill's anticipated release in 2025 signals a transformative milestone in pain management, offering a novel and accessible alternative to traditional treatments.

While CBD has gained recognition for its potential therapeutic properties, this trial aims to solidify its status as a reputable and effective solution for chronic pain. The expected cost of approximately $68 for a month's treatment positions the CBD pill as a competitive and viable option in the pain relief market.

Australia's foray into pioneering cannabis-based medicine underscores its commitment to addressing the evolving needs of patients and advancing the global conversation on the role of cannabinoids in healthcare. As the clinical trial progresses, the world awaits the potential introduction of this groundbreaking CBD pill, poised to redefine the landscape of chronic pain management.


Lydia K. (Bsc. RN) is a cannabis writer, which, considering where you’re reading this, makes perfect sense. Currently, she is a regular writer for Mace Media. In the past, she has written for MyBud, RX Leaf & Dine Magazine (Canada), CBDShopy (UK) and Cannavalate & Pharmadiol (Australia). She is best known for writing epic news articles and medical pieces. Occasionally, she deviates from news and science and creates humorous articles. And boy doesn't she love that! She equally enjoys ice cream, as should all right-thinking people.